(Total Views: 203)
Posted On: 07/11/2019 5:42:33 PM
Post# of 145915
![Avatar](https://investorshangout.com/images/ProfileImages/947101588_48586_morph.jpg)
Interesting article just out, 38 authors, yes 38, looking at many different receptors with cancer.
http://cancerdiscovery.aacrjournals.org/conte...1.full.pdf
part of abstract
We show iαβT cells induce a CCR5 -dependent immunogenic macrophage reprogramming, thereby enabling marked CD4+ and CD8 + T cell expansion/activation and tumor protection. Collectively, iαβ Ts govern fundamental intra-tumoral crosstalk between innate and adaptive immune populations and are attractive therapeutic targets.
Significance
We found that innate αβ T cells (iαβTs) are a profoundly activated T cell subset in PDA that slow tumor growth in murine and human models of disease. iαβTs induce a CCR5 -dependent immunogenic TAM program, T cell activation and expansion, and should be considered as novel targets for immunotherapy
http://cancerdiscovery.aacrjournals.org/conte...1.full.pdf
part of abstract
We show iαβT cells induce a CCR5 -dependent immunogenic macrophage reprogramming, thereby enabling marked CD4+ and CD8 + T cell expansion/activation and tumor protection. Collectively, iαβ Ts govern fundamental intra-tumoral crosstalk between innate and adaptive immune populations and are attractive therapeutic targets.
Significance
We found that innate αβ T cells (iαβTs) are a profoundly activated T cell subset in PDA that slow tumor growth in murine and human models of disease. iαβTs induce a CCR5 -dependent immunogenic TAM program, T cell activation and expansion, and should be considered as novel targets for immunotherapy
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)